Our novel pipeline of therapies for neurological and psychiatric disease is based on decades of research focused on cognitive neuroscience and the neurobiology of the aging brain.

Research at Johns Hopkins and leading research centers around the world have demonstrated that overactivity in key brain circuits contributes to cognitive impairment and drives neurodegeneration if not controlled.

This overactivity is a characteristic feature of amnestic mild cognitive impairment (aMCI) due to Alzheimer’s disease (or prodromal AD), the earliest symptomatic stage of characterized by memory loss. Overactivity detected by brain imaging predicts the extent of neurodegeneration in the earliest stages of aMCI and clinical progression to dementia.

Our most advanced clinical program targets aMCI. We believe we have the potential to deliver the first and only therapeutic for hippocampal overactivity and potentially the first therapeutic to slow progression and delay the onset of Alzheimer’s dementia.


Our Phase 3-ready asset is intended to treat aMCI and delay progression to Alzheimer’s dementia. We plan to initiate our Phase 3 HOPE4MCI trial in 2017.

Discovery: GABAA α5 positive allosteric modulators

Our novel late-stage discovery program offers therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. We expect to submit an Investigational New Drug (IND) application in 2017.